bsm-52309R [Primary Antibody]
NFkB p105/p50 (12G3) Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: NFkB p105/p50

Clonality: Monoclonal

Isotype: IgG

Entrez Gene: 4790

Swiss Prot: P19838

Source: Recombinant human NFkB p105/ p50 between 300 to 400 amino acids

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor, but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function, although processing of NFKB1/p105 also appears to occur post-translationally.

Size: 100ul

Concentration: 1ug/ul

Predicted Molecular Weight: 50/105 kDa


Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Paraformaldehyde-fixed and paraffin-embedded Human tonsil tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human spleen tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Paraformaldehyde-fixed and paraffin-embedded Mouse bladder tissue incubated with NFkB p105/p50 (12G3) Monoclonal Antibody (bsm-52309R) at 1:100, overnight at 4°C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.


Lane 1: Human Raji cell lysates; Lane 2: Human MCF-7 cell lysates; Lane 3: Human Jurkat cell lysates; Lane 4: Human A431 cell lysates; Lane 5: Human HeLa cell lysates probed with NFKB1 Monoclonal Antibody, Unconjugated (bsm-52309R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.